MT1

MT1 is a linear synthetic analog of α-MSH in which norleucine and D-phenylalanine substitutions stabilise the sequence relative to the native hormone. That design places it in the afamelanotide structural class used in melanocortin research.

It must not be confused with Melanotan II. MT-2 is cyclic; MT1 is linear. The two have different masses, chromatographic behaviour and catalog documentation, and VaultLabs never shares lot numbers between them.

Pharmaceutical afamelanotide implants approved for specific indications in some jurisdictions are finished medicines. VaultLabs MT1 is laboratory reference material only.

Published work covers melanocortin-1 receptor pharmacology, melanogenesis models and clinical literature on afamelanotide in erythropoietic protoporphyria — the latter describing a regulated pharmaceutical product, not research-grade powder.

For laboratories, legitimate uses are analytical and receptor-pharmacology reference work. VaultLabs makes no cosmetic or clinical claims.

Release is by HPLC with a lot-linked certificate. Laboratories holding both MT1 and MT-2 should treat unambiguous identification as part of goods-in handling.

Store sealed lyophilised vials at 2–8 °C, protected from light and humidity. MT1 is not an approved medicine and is not for human use.

VaultLabs MT1 is supplied strictly for in vitro laboratory research. Orders indicating intended human use are declined.

The catalog presentation is a 10 mg lyophilised vial with batch verification when a COA is published.

Because consumer interest in melanocortin peptides is high, VaultLabs applies institutional checks in full for MT1 orders and declines any request that indicates intended human application, tanning use or veterinary administration outside approved research contexts.

Analytical laboratories holding MT1 alongside MT-2 or PT-141 should maintain separate inventory locations and certificate files. The mass differences are real but small enough relative to operator error that label-only identification is not sufficient for high-stakes method work.

Published pharmaceutical literature on afamelanotide implants describes a finished medicine under a specific indication. That regulatory status does not transfer to research-grade lyophilised powder and must not be cited as authorisation for personal use of catalog material.

This monograph is a reference article for laboratory purchasers and documentation staff. It summarises chemical identity, literature context and handling constraints that affect analytical work. It is not a protocol, not a dosing guide and not a substitute for institutional SOP review.

Where pharmaceutical or clinical papers are cited, they are included only to anchor compound identity and regulatory status. They do not authorise human use of VaultLabs research material, and they do not convert a lyophilised reference vial into a finished medicine.

If a certificate, label and monograph appear to disagree, stop and query support with the lot number before the material enters an experiment. Lot-linked certificates override general catalog copy for the specific unit in hand.

VaultLabs updates monographs when catalog strengths or documentation practice change. The updatedAt field marks the editorial revision date for this article, not the manufacture date of any particular lot.

All VaultLabs materials named here remain research-use-only: not for human consumption, not for medical use, and not for personal application under any reading of the surrounding literature.

MC1R binding and melanogenesis models

Comparative melanocortin analog pharmacology

Analytical identification versus MT-2 / PT-141

2–8 °C (lyophilized, sealed)

2–8 °C sealed lyophilized storage, protected from light.

Linear melanocortin peptides require cold, light-protected sealed storage and careful handling after reconstitution.